The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TNFA | -96.31% | -99.96% | -79.23% | -100% |
| S&P | +14.78% | +87.14% | +13.33% | +68% |
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.
No news articles found for TNF Pharmaceuticals, Inc..
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $7.41M | 85.1% |
| Market Cap / Employee | $3.71M | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | -$2,811.39K | -45.7% |
| EBITDA | -$1,788.66K | 2.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.90M | 479.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.45% | 77.7% |
| Return On Invested Capital | -90.78% | -24.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,160.27K | 68.1% |
| Operating Free Cash Flow | -$1,160.27K | 68.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.40 | 0.30 | 0.70 | 0.24 | -1.33% |
| Price to Tangible Book Value | 46.34 | 14.10 | -46.50 | -0.23 | -99.38% |
| Enterprise Value to EBITDA | -0.20 | -0.52 | -2.45 | -1.85 | -153.60% |
| Return on Equity | -169.9% | -121.9% | -115.4% | -40.6% | -71.52% |
| Total Debt | $10.58K | $2.68K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
